Literature DB >> 2809645

Reduced rapid eye movement sleep latency in patients with Parkinson's disease.

V S Kostić1, V Susić, N Covicković-Sternić, Z Marinković, S Janković.   

Abstract

Rapid eye movement (REM) sleep latency (time from sleep onset to the first REM episode) was measured in 39 patients with idiopathic Parkinson's disease. Reduced REM sleep latency (less than or equal to 65.0 min) was found in a high proportion of patients (69%). Since reduced REM sleep latency may be a trait-like abnormality relatively specific to primary depression, we evaluated this parameter in two groups of parkinsonian patients: depressed (16 patients) and non-depressed (23 patients). Its incidence was significantly higher in depressed patients with Parkinson's disease.

Entities:  

Mesh:

Year:  1989        PMID: 2809645     DOI: 10.1007/bf00314903

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  26 in total

1.  Successful separation of depressed, normal, and insomniac subjects by EEG sleep data.

Authors:  J C Gillin; W Duncan; K D Pettigrew; B L Frankel; F Snyder
Journal:  Arch Gen Psychiatry       Date:  1979-01

2.  [Influence of L-DOPA on night sleep in parkinsonian patients].

Authors:  K Kendel; U Beck; C Wita; E Hohneck; H Zimmermann
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1972

3.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

4.  Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability.

Authors:  R H Mindham; C D Marsden; J D Parkes
Journal:  Psychol Med       Date:  1976-02       Impact factor: 7.723

5.  EEG studies of sleep in the diagnosis of depression.

Authors:  M Feinberg; J C Gillin; B J Carroll; J F Greden; A P Zis
Journal:  Biol Psychiatry       Date:  1982-03       Impact factor: 13.382

6.  Sleep EEG and dexamethasone suppression test findings in outpatients with unipolar major depressive disorders.

Authors:  A J Rush; D E Giles; H P Roffwarg; C R Parker
Journal:  Biol Psychiatry       Date:  1982-03       Impact factor: 13.382

7.  Reduced rapid eye movement latency. A predictor of recurrence in depression.

Authors:  D E Giles; R B Jarrett; H P Roffwarg; A J Rush
Journal:  Neuropsychopharmacology       Date:  1987-12       Impact factor: 7.853

8.  REM latency: a psychobiologic marker for primary depressive disease.

Authors:  D J Kupfer
Journal:  Biol Psychiatry       Date:  1976-04       Impact factor: 13.382

9.  Depression in Parkinson's disease: a quantitative and qualitative analysis.

Authors:  A M Gotham; R G Brown; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-04       Impact factor: 10.154

10.  Polysomnographic findings in recently drug-free and clinically remitted depressed patients.

Authors:  A J Rush; M K Erman; D E Giles; M A Schlesser; G Carpenter; N Vasavada; H P Roffwarg
Journal:  Arch Gen Psychiatry       Date:  1986-09
View more
  4 in total

Review 1.  Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

Authors:  Jennifer C Felger; Andrew H Miller
Journal:  Front Neuroendocrinol       Date:  2012-09-21       Impact factor: 8.606

Review 2.  Fighting insomnia and battling lethargy: the yin and yang of palliative care.

Authors:  Mellar P Davis; Harold Goforth
Journal:  Curr Oncol Rep       Date:  2014-04       Impact factor: 5.075

3.  REM sleep latency as an independent risk for cardiovascular events in hemodialysis patients.

Authors:  Shigeichi Shoji; Masaaki Inaba; Koichiro Yoda; Hisanori Okazaki; Mio Toyokawa; Kyoko Norimine; Tomoyuki Yamakawa; Senji Okuno
Journal:  Physiol Rep       Date:  2021-05

4.  Association between poor glycemic control, impaired sleep quality, and increased arterial thickening in type 2 diabetic patients.

Authors:  Koichiro Yoda; Masaaki Inaba; Kae Hamamoto; Maki Yoda; Akihiro Tsuda; Katsuhito Mori; Yasuo Imanishi; Masanori Emoto; Shinsuke Yamada
Journal:  PLoS One       Date:  2015-04-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.